Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress.

Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress.
复制标题

奥拉帕尼通过核仁应激诱导 RPL5/RPL11 依赖性 p53 激活

DOI:
10.3389/fonc.2022.821366
复制
发表时间:
2022
影响因子:
4.7
通讯作者:
--
中科院分区:
医学3区
文献类型:
--
作者:

文献摘要

参考文献

被引文献

相似文献

聚ADP核糖聚合酶(PARP)抑制剂(PARPi)奥拉帕尼是一种广泛用于BRCA 1/2或其他DNA修复基因突变引起的多种同源重组缺陷(HRD)实体瘤的靶向治疗药物。奥拉帕尼的抗肿瘤活性在很大程度上归因于其抑制PARP酶和阻断DNA单链断裂(SSB)修复的能力,这最终导致HRD细胞中最有害的DNA损伤,双链断裂(DSB)。虽然PARPi被发现诱导p53依赖性细胞死亡,但其潜在的分子机制仍不完全清楚。在这里,我们报告说,奥拉帕尼治疗导致p53稳定和激活其下游靶基因的剂量和时间依赖性的方式。从机制上讲,奥拉帕尼通过抑制核糖体RNA前体(pre-rRNA)的生物合成触发核仁应激,导致核糖体蛋白(RP)、RPL 5和RPL 11与MDM 2之间的相互作用增强。因此,RPL 5和RPL 11的敲低阻止了奥拉帕尼诱导的p53活化。更重要的是,奥拉帕尼通过激活p53有效抑制乳腺癌和结直肠癌细胞的存活和增殖。总之,我们的研究表明,奥拉帕尼激活核仁应激-RPs-p53通路,表明rRNA生物合成是PARPi的新靶点。
The poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) Olaparib is a widely used targeted therapy for a variety of solid tumors with homologous recombination deficiency (HRD) caused by mutation of BRCA1/2 or other DNA repair genes. The anti-tumor activity of Olaparib has been largely attributed to its ability to inhibit PARP enzymes and block DNA single-strand break (SSB) repair, which eventually leads to the most detrimental DNA damage, double-strand breaks (DSB), in HRD cells. Although PARPi was found to induce p53-dependent cell death, the underlying molecular mechanism remains incompletely understood. Here, we report that Olaparib treatment leads to p53 stabilization and activation of its downstream target genes in a dose- and time-dependent manner. Mechanistically, Olaparib triggers nucleolar stress by inhibiting biosynthesis of the precursor of ribosomal RNAs (pre-rRNA), resulting in enhanced interaction between ribosomal proteins (RPs), RPL5 and RPL11, and MDM2. Consistently, knockdown of RPL5 and RPL11 prevents Olaparib-induced p53 activation. More importantly, Olaparib efficiently suppresses breast and colorectal cancer cell survival and proliferation through activation of p53. Altogether, our study demonstrates that Olaparib activates the nucleolar stress-RPs-p53 pathway, suggesting rRNA biogenesis as a novel target for PARPi.
DOI: 10.1016/j.ccr.2010.08.007
发表时间: 2010-09-14
期刊: Cancer cell
影响因子: 50.3
作者:
Macias E;Jin A;Deisenroth C;Bhat K;Mao H;Lindström MS;Zhang Y
通讯作者: Zhang Y
DOI: 10.1016/0092-8674(93)90546-3
发表时间: 1993-12-03
期刊: CELL
影响因子: 64.5
作者:
FISHEL, R;LESCOE, MK;KOLODNER, R
通讯作者: KOLODNER, R
长链非编码 RNA RMRP 灭活肿瘤抑制因子 p53
DOI: 10.1073/pnas.2026813118
发表时间: 2021-07-20
影响因子: 11.1
作者:
Chen Y;Hao Q;Wang S;Cao M;Huang Y;Weng X;Wang J;Zhang Z;He X;Lu H;Zhou X
通讯作者: Zhou X
DOI: 10.1038/nrm.2017.53
发表时间: 2017-10
期刊: Nature reviews. Molecular cell biology
影响因子: --
作者:
Ray Chaudhuri A;Nussenzweig A
通讯作者: Nussenzweig A
DOI: 10.1038/358080a0
发表时间: 1992-07-02
期刊: NATURE
影响因子: 64.8
作者:
OLINER, JD;KINZLER, KW;VOGELSTEIN, B
通讯作者: VOGELSTEIN, B